Chungbuk National University Hospital
Cheongju-si, South Korea
NCT Number: NCT04500132
Prevention of COVID-19 infection to severe pneumonea or ARDS
Looking for future studies?
Notify Me19 year and older
All sexes
Interventional
Phase 2
Cheongju-si, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
EC-18 QD
Placebo EC-18 QD
Time frame: 14 days after starting IP administration
Enzychem Lifesciences Corporation
Industry
Phase 2, Multi-center, Randomized, Double-blind, Placebo- Controlled Study to Evaluate the Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06795880
COVID-19, Coronaviridae Infections
İzmit, Kocaeli, Turkey (Türkiye)
View Trial DetailsNCT07758296
Adherence Interventions, Behavior
Columbia, South Carolina, United States
View Trial DetailsNCT07758309
Adherence Interventions, Behavior
Columbia, South Carolina, United States
View Trial DetailsNCT04481633
COVID-19, Coronaviridae Infections
Limoges, France
View Trial Details